# US 6,730,778 B2 · Human sel-10 polypeptides and polynucleotides that encode them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,778 B2
- Document ID: US6730778B2
- Status: Granted
- Kind: B2
- Application number: 09/328,877
- Filed: 1999-06-09
- Published: 2002-11-28
- Granted: 2004-05-04
- Earliest claimed: 1997-12-19
- Assignees: Pharmacia & Upjohn Company
- Inventors: Mark E. Gurney; Adele M. Pauley; Jinhe Li
- Web page: https://patentgrep.com/patent/US6730778B2

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which Aβ processing is altered.

## Claims

### Claim 1

An isolated human sel-10 polypeptide comprising SEQ ID NO:7.

### Claim 2 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:3.

### Claim 3 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:4.

### Claim 4 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:5.

### Claim 5 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:6.

### Claim 6 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:8.

### Claim 7 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:9.

### Claim 8 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:21.

### Claim 9 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:25.

### Claim 10 (depends on 1)

The isolated sel-10 polypeptide of claim 1, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:27.
